Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein

Cancer Research

Volumn 65, Issue 19, 2005, Pages 8993-9003

  Lee, Ji Hee ^a   Cho, Eun Song ^a   Kim, Mi Young ^a   Seo, Young Woo ^b   Kho, Dhong Hyo ^a   Chung, Ik Joo ^a   Kook, Hyun ^a   Kim, Nack Sung ^a   Ahn, Kyu Youn ^a   Kim, Kyung Keun ^a  

^a Chonnam National University Medical School   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTIMETASTATIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; FIBRONECTIN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 2; KITENIN; PROTEIN 90K; PROTEIN KINASE C INHIBITOR; PSUPER KITENIN; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CELL CULTURE; COLON TUMOR; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; METASTASIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; T LYMPHOCYTE; TAIL; TUMOR VOLUME; TWO HYBRID SYSTEM; YEAST;

ADENOCARCINOMA; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; DNA, ANTISENSE; GLYCOPROTEINS; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-1; INTERLEUKIN-6; MACROPHAGES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PROTEIN KINASE C; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 25444475212     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0590     Document Type: Article

References (32)

1. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32.
2. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000;12:571-5.
3. Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum Gene Ther 2000;11:1269-75.
4. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986;46:3005-10.
5. Iacobelli S, Arno E, Sismondi P, et al. Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat 1988;11:19-30.
6. Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci 1994;19:5-8.
7. Ullrich A, Sures I, D'Egidio M, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994;269:18401-7.
8. Jallal B, Powell J, Zachwieja J, et al. Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res 1995;55:3223-7.
9. Powell TJ, Schreck R, McCall M, et al. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol 1995;17:209-21.
10. Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004;19:551-6.
11. Lee JH, Park SR, Chay KO, et al. KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer. Cancer Res 2004;64:4235-43.
12. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 2004;25:22-8.
13. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
14. Lee JH, Seo YW, Park SR, Kim YJ, Kim KK. Expression of splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression. Cancer Res 2003;63:7247-55.
15. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327:761-6.
16. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993;268:14245-9.
17. Andre S, Pieters RJ, Vrasidas I, et al. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. Chembiochem 2001;2:822-30.
18. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001;91:167-72.
19. Rotteveel FT, Verhoef MH, de Rijk R, van den Berg H, Wolvers DA, Berkenbosch F. Both interleukin-1 α and interleukin-1 β are involved as accessory signals in primary antigen (tetanus toxoid) induced human T-cell activation. Cell Immunol 1991;138:245-50.
20. Schmitt E, Beuscher HU, Huels C, et al. IL-1 serves as a secondary signal for IL-9 expression. J Immunol 1991;147:3848-54.
21. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-78.
22. Grassadonia A, Tinari N, Fiorentino B, et al. The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones. γ-interferon, and double-strand polynucleotides. Endocrinology 2004;145:4728-36.
23. Iacobelli S, Sismondi P, Giai M, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69:172-6.
24. Marchetti A, Tinari N, Buttitta F, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002;62:2535-9.
25. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996;56:4530-4.
26. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
27. 2+-binding proteins from bovine brain including a potent inhibitor of protein kinase C. Biochem J 1985;232;559-67.
28. Klein MG, Yao Y, Slosberg ED, Lima CD, Doki Y, Weinstein IB. Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family. Exp Cell Res 1998;244:26-32.
29. Brzoska PM, Chen H, Zhu Y, et al. The product of the ataxia- telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci U S A 1995;92:7824-8.
30. Razin E, Zhang ZC, Nechushtan H, et al. Suppression of microphthalmia transcriptional activity by its association with protein kinase C-interacting protein 1 in mast cells. J Biol Chem 1999;274:34272-6.
31. Korsisaari N, Makela TP. Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins. J Biol Chem 2000;275:34837-40.
32. Su T, Suzui M, Wang L, Lin CS, Xing WQ, Weinstein IB. Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci U S A 2003;100:7824-9.